EGFR and non-small cell lung carcinoma: Similarly, phase III randomized trials in Japanese and Indian population (NEJ009) also proved that a combination (pemetrexed+carboplatin+gefitinib), compared to single gefitinib, significantly prolonged PFS and OS in NSCLC patients with EGFR mutations [27, 28].